Nicolas Roydon Smoll

Nicolas Roydon Smoll

Auto-generated profile, based on publicly available information

Nicolas Roydon Smoll

Affiliation Sunshine Coast Public Health Unit, Maroochydore, Queensland, Australia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2012 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
NSNicolas R. Smoll
Nicolas R. Smoll
KDKatharine J. Drummond
Katharine J. Drummond

15 March 2013 in Cancer
Verified
Journal Article
Open access
PDF file
NSNicolas R. Smoll
Nicolas R. Smoll
OGOliver P. Gautschi
Oliver P. Gautschi
IRIvan Radovanovic
Ivan Radovanovic
KSKarl Schaller
Karl Schaller
DWDamien C. Weber
Damien C. Weber
BACKGROUND: Chordomas are rare bone tumors arising from remnants of the embryonic notochord.METHODS: Data for this study were obtained from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (1973‐2009) to calculate the incidence, relative survival (RS), and standardized mortality ratio (SMR) of patients diagnosed with intracranial and extracranial chordomas and to assess the effects of age and sex on this disease.RESULTS: The overall incidence of extracranial and intracranial chordomas was 8.4 per 10 million population. The median overall survival of patients with chordoma patients was 7.7 years. The median survival was 7.7 years for male patients and 7.8 years for female patients. Younger patients (aged <40 years) survived longer compared with older patients (10‐year RS, 68% vs 43%). The estimated age‐standardized 5‐year, 10‐year, and 20‐year RS rates was 72%, 48%, and 31%, respectively. The SMR in the overall cohort was 4.6 (95% confidence interval, 4.22‐5.0) or 21.0 (95% confidence interval, 16.6‐27.2) in young adult patients and 3.0 (95% confidence interval, 2.6‐3.4) in elderly patients.CONCLUSIONS: The elderly had a more aggressive form of this disease; and, other than the incidence, sex did not influence outcome in this disease. The study of chordomas presents a good case for the contribution that the SMR can have on measuring the impact of a disease on a population of patients. Although the younger population has better survival rates, the impact (SMR) in the younger age groups is much higher than in older populations. Cancer 2013;119:2029–2037. © 2013 American Cancer Society.

8 December 2009 in Clinical Anatomy
Verified
Journal Article
Closed access
PDF file
NSNicolas Roydon Smoll
Nicolas Roydon Smoll

1 February 2018 in Stroke
Verified
Journal Article
Closed access
PDF file
Martin N. StienenMartin N. Stienen
Martin N. Stienen
MGMenno Germans
Menno Germans
JBJan-Karl Burkhardt
Jan-Karl Burkhardt
MNMarian C. Neidert
Marian C. Neidert
CFChristian Fung
Christian Fung
MCMarco Corniola
Marco Corniola
Background and Purpose—: To identify predictors of in-hospital mortality in patients with aneurysmal subarachnoid hemorrhage and to estimate their impact. Methods—: Retrospective analysis of prospective data from a nationwide multicenter registry on all aneurysmal subarachnoid hemorrhage cases admitted to a tertiary neurosurgical department in Switzerland (Swiss SOS [Swiss Study on Aneurysmal Subarachnoid Hemorrhage]; 2009–2015). Both clinical and radiological independent predictors of in-hospital mortality were identified, and their effect size was determined by calculating adjusted odds ratios (aORs) using multivariate logistic regression. Survival was displayed using Kaplan–Meier curves. Results—: Data of n=1866 aneurysmal subarachnoid hemorrhage patients in the Swiss SOS database were available. In-hospital mortality was 20% (n=373). In n=197 patients (10.6%), active treatment was discontinued after hospital admission (no aneurysm occlusion attempted), and this cohort was excluded from analysis of the main statistical model. In the remaining n=1669 patients, the rate of in-hospital mortality was 13.9% (n=232). Strong independent predictors of in-hospital mortality were rebleeding (aOR, 7.69; 95% confidence interval, 3.00–19.71; P <0.001), cerebral infarction attributable to delayed cerebral ischemia (aOR, 3.66; 95% confidence interval, 1.94–6.89; P <0.001), intraventricular hemorrhage (aOR, 2.65; 95% confidence interval, 1.38–5.09; P =0.003), and new infarction post-treatment (aOR, 2.57; 95% confidence interval, 1.43–4.62; P =0.002). Conclusions—: Several—and among them modifiable—factors seem to be associated with in-hospital mortality after aneurysmal subarachnoid hemorrhage. Our data suggest that strategies aiming to reduce the risk of rebleeding are most promising in patients where active treatment is initially pursued. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT03245866.

13 January 2017 in Neurosurgery
Verified
Journal Article
Closed access
PDF file
OGOliver P. Gautschi
Oliver P. Gautschi
MSMartin N. Stienen
Martin N. Stienen
MCMarco V. Corniola
Marco V. Corniola
HJHolger Joswig
Holger Joswig
KSKarl Schaller
Karl Schaller
NSNicolas R. Smoll
Nicolas R. Smoll
BACKGROUND: The Timed Up and Go Test (TUG Test) has previously been described as a reliable tool to evaluate objective functional impairment in patients with degenerative disc disease. OBJECTIVE: The aim of this study was to assess the minimum clinically important difference (MCID) of the TUG Test. METHODS: The TUG Test (measured in seconds) was correlated with validated patient-reported outcome measures (PROs) of pain intensity (Visual Analog Scale for back and leg pain), functional impairment (Oswestry Disability Index, Roland Morris Disability Index), and health-related quality of life measures (Short Form-12 and EuroQol 5D). Three established methods were used to establish anchor-based MCID values using responders of the following PROs (Visual Analog Scale back and leg pain, Oswestry Disability Index, Roland Morris Disability Index, EuroQol 5D index, and Short Form-12 Physical Component Summary) as anchors: (1) average change, (2) minimum detectable change, and (3) change difference approach. RESULTS: One hundred patients with a mean ± SD age of 56.2 ± 16.1 years, 57 (57%) male, 45 patients undergoing microdiscectomy, 35 undergoing lumbar decompression, and 20 undergoing fusion surgery were studied. The 3 MCID computation methods revealed a range of MCID values according to the PRO used from 0.9 s (Oswestry Disability Index based on the change difference approach) to 6.0 s (EuroQol 5D index based on the minimum detectable change approach), with a mean MCID of 3.4 s for all measured PROs. CONCLUSION: The MCID for the TUG Test time is highly variable depending on the computation technique used. The average TUG Test MCID was 3.4 s using all 3 methods and all anchors.

1 May 2013 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
NSNicolas R. Smoll
Nicolas R. Smoll
KSKarl Schaller
Karl Schaller
OGOliver P. Gautschi
Oliver P. Gautschi